Please ensure Javascript is enabled for purposes of website accessibility
Skip to main content

Thank you for supporting journalism at your local newspaper. This article is available exclusively for our subscribers, who help fund our work at Crestview News Bulletin.

columns, more-voices, Opinion

LADD: Drug price controls will hurt patients

| archive
Patients are raving about a series of newer, more effective medicines. There's just one catch. These drugs are really expensive. Xeljanz, a new rheumatoid arthritis drug, costs $25,000 a year. So…


The remainder of this article is available only for our website subscribers, who help fund our mission of keeping you updated on news you want and need to know. You can become a subscriber for as little as $5.67 a month.

error: Content is protected !!